The Ninth Circuit agreed to fast-track an appeal from OpenAI Inc. and a hardware startup it owns challenging a temporary ban ...

IO Biotech files for the sale of up to 5.6M shares of common stock for holders May 23, 2025 4:17 PM ET IO Biotech, Inc. (IOBT) Stock By: Nivedita Hazra, SA News Editor Play (<1min) ...

IO Biotech’s progress includes promising data from a Phase 2 basket trial and ongoing development of its T-win platform for cancer immunotherapy.

IO Biotech Presents New Data at AACR 2025 Supporting Dual Mechanism and Immune Activation of Cancer Vaccines IO102-IO103 and IO170 ...

NEW YORK, March 18, 2025 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company, has been named to Fast Company’s prestigious list of the World’s Most ...

NEW YORK, March 04, 2025 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines, today ...

IO Biotech (NASDAQ:IOBT – Get Free Report) is projected to release its earnings data on Tuesday, March 4th. Analysts expect IO Biotech to post earnings of ($0.39) per share for the quarter.

NEW YORK - IO Biotech (IOBT), a clinical-stage biopharmaceutical company valued at $58.63 million, has published results from a preclinical study on its second cancer vaccine candidate, IO112 ...

IO Biotech is advancing its lead cancer vaccine candidate, IO102-IO103, in clinical trials, and additional pipeline candidates through preclinical development.